Vanderbilt University Medical Center in Nashville, Tenn., will receive $1 million as part of drug manufacturer Solvay's $16.5 million settlement of a class-action lawsuit related to its hormone replacement drug, according to a Nashville Business Journal report.
The total settlement is the result of a suit filed by consumers against Solvay, which manufactures Estratest, the hormone replacement drug that was allegedly falsely advertised and misrepresented.
Vanderbilt has been directed by the court to use its $1 million for research and education related to the health of women experiencing menopause. The order was issued by the U.S. District Court for the District of Minnesota.
Read the Nashville Business Journal report on Vanderbilt University Medical Center.
Read more about Vanderbilt:
- Vanderbilt Exec Predicts $216M in Uncompensated Care for 2010
- Vanderbilt Names Luke Gregory as Permanent CEO of Children's Hospital
- Vanderbilt Research Team Studies Robots in EDs
The total settlement is the result of a suit filed by consumers against Solvay, which manufactures Estratest, the hormone replacement drug that was allegedly falsely advertised and misrepresented.
Vanderbilt has been directed by the court to use its $1 million for research and education related to the health of women experiencing menopause. The order was issued by the U.S. District Court for the District of Minnesota.
Read the Nashville Business Journal report on Vanderbilt University Medical Center.
Read more about Vanderbilt:
- Vanderbilt Exec Predicts $216M in Uncompensated Care for 2010
- Vanderbilt Names Luke Gregory as Permanent CEO of Children's Hospital
- Vanderbilt Research Team Studies Robots in EDs